Patent details
EP2637661 Title: Use of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)- pyridin-4-yl]-thiazol-2-yl}-amide) in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
Basic Information
- Publication number:
- EP2637661
- PCT Application Number:
- EP2011069522
- Type:
- European Patent Granted for LU
- Legal Status:
- Lapsed
- Application number:
- EP117821116
- PCT Publication Number:
- WO2012062694
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- Use of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)- pyridin-4-yl]-thiazol-2-yl}-amide) in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
- French Title of Invention:
- Utilisation de la 1-({4-méthyl-5-[2-(2,2,2-trifluoro- 1,1-diméthyléthyl)- pyridin-4-yl]thiazole-2-yl}-amide) du 2-amide de l'acide (S)-pyrrolidine-1,2-dicarboxylique dans le traitement de maladies dépendantes d'EGFR ou de maladies qui ont acquis une résistance aux agents qui ciblent des membres de la famille d'EGFR
- German Title of Invention:
- Verwendung von (S)-Pyrrolidin-1,2-Dicarbonsäure-2-Amid 1 - ({4-Methyl-5- [2- (2,2,2-Trifluor-1,1-Dimethylethyl)Pyridin-4- yl] Thiazol-2-yl}Amid) zur Behandlung von EGFR-abhängigen Erkrankungen oder Erkrankungen mit erworbener Resistenz gegenüber Wirkstoffen, die auf EGFR-Familienmitglieder gerichtet sind
- SPC Number:
Dates
- Filing date:
- 07/11/2011
- Grant date:
- 20/12/2017
- EP Publication Date:
- 18/09/2013
- PCT Publication Date:
- 18/05/2012
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 20/12/2017
- EP B1 Publication Date:
- 20/12/2017
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- 07/11/2018
- Expiration date:
- 07/11/2031
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 13/12/2017
- Name:
- Novartis AG
- Address:
- Lichtstrasse 35, 4056 Basel, Switzerland (CH)
Inventor
1
- Name:
- MAIRA, Sauveur-Michel
- Address:
- Switzerland (CH)
2
- Name:
- SCHNELL, Christian René
- Address:
- Switzerland (CH)
3
- Name:
- GARCIA-ECHEVERRIA, Carlos
- Address:
- France (FR)
4
- Name:
- FRITSCH, Christine
- Address:
- Switzerland (CH)
5
- Name:
- BRACHMANN, Saskia Maria
- Address:
- Switzerland (CH)
Priority
- Priority Number:
- 411117 P
- Priority Date:
- 08/11/2010
- Priority Country:
- United States (US)
Classification
- IPC classification:
- A61K 31/4439; A61K 31/517; A61K 39/00; A61K 39/395; A61K 45/06; A61P 35/00; C07K 16/32;
Publication
European Patent Bulletin
- Issue number:
- 201751
- Publication date:
- 20/12/2017
- Description:
- Grant (B1)
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|---|---|
| 30/03/2019 | Outgoing Correspondence | 1 |